CHEK1 and triple-negative breast carcinoma: Indeed, EGFR activation with EGF reduced cellular sensitivity to CHK1 inhibition, and conversely, inhibition of EGFR with erlotinib enhanced cellular cytotoxicity with prexasertib in several in vitro and in vivo models of triple negative breast cancer.